<DOC>
	<DOCNO>NCT00300365</DOCNO>
	<brief_summary>- Aim 1 : We test primary hypothesis combine niacin extend release ( niacin-ER ) , daily dosage 2.0 g pioglitazone , daily dosage 45 mg result 12 % great increase HDL-C compare niacin-ER monotherapy 12 week non-diabetic patient metabolic syndrome ( see Table 1 ) . - Aim 2 : In secondary aim , test hypothesis combination niacin-ER pioglitazone significantly increase insulin sensitivity , compare niacin-ER alone , measure frequently sample intravenous glucose tolerance test ( FSIGTT ) . - Aim 3 : In additional secondary aim , test hypothesis combination pioglitazone niacin-ER reduce marker inflammation , include C-reactive protein ( CRP ) , interleukin-6 ( IL-6 ) , soluble tumor necrosis factor alpha receptor type II ( sTNF--R2 ) , resistin , raise adiponectin compare niacin-ER alone . - Aim 4 : In exploratory aim , measure broad spectrum emerge cardiovascular risk factor order derive rich sense effect combination pioglitazone niacin-ER individual . We collect adipose tissue level expression ( mRNA &amp; protein ) relate cholesterol transport ( PPAR- , PPAR- , PPAR- , ABCA1 , ABCG1 , SR-B1 ) , triglyceride transport/lipolysis ( HM74a , HSL ) , adipocytokines ( TNF-a , IL-6 , adiponectin , leptin , acylation-stimulating protein ) , glucose regulation ( glut-4 IRS-1 ) . [ assume sufficient mRNA yield ] . These finding serve hypothesis-generating data future studies..</brief_summary>
	<brief_title>Pioglitazone Vs Placebo Combination With Niacin Extended Release Low HDL</brief_title>
	<detailed_description>This two-arm , parallel , double-blind randomize prospective clinical trial . The subject ask provide informed consent , undergo screen enrollment criterion first visit ( -5 week ) . The subject eligible , provide informed consent return Visit 2 baseline data ( -4 week ) , begin unblinded niacin-ER titration . Specifically , subject receive start dose niacin-ER 500 mg per day , increase 500 mg increment every week dose 2000 mg per day . Subjects need tolerate least 1500 mg per day niacin-ER order remain study randomize . Thus subject unable tolerate 2000 mg daily dose niacin-ER take back 1500 mg per day one week randomize . Subjects develop prohibitive side effect dose less 1500 mg per day discontinue study . All subject able take target dose niacin-ER continue dose niacin-ER come GCRC randomize 1:1 fashion either niacin-ER plus pioglitazone niacin-ER plus matching placebo 12 week . Pioglitazone start 30 mg increase 45 mg week 6 . This entry design design minimize difference mean dose niacin-ER dropout rate study group .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Men woman age 18 75 2 . HDLC ≤ 40 mg/dL Men HDLC &lt; 50 mg/dl Women* 3 . At least two follow criterion ( , b , c , ) list : 1 . Abdominal obesity ( waist circumference : men 40 inch woman 35 inch ) ** 2 . Blood pressure &gt; 130/ &gt; 85 mmHg untreated patient OR use antihypertensive agent . 3 . Fasting glucose &gt; 100 mg/dL &lt; 126 mg/dL . 4 . Fasting triglyceride &gt; 150 mg/dL 1 . Diabetes use antihyperglycemic medication last 3 month ( subject fast blood glucose &gt; 110 mg/dL OGTT rule diabetes mellitus ) . 2 . Subjects statin therapy may enrol , stable dose least 3 month , expect require titration statin therapy course study . 3 . Uncontrolled hypertension ( define systolic blood pressure &gt; 180 , diastolic blood pressure &gt; 100 ) . 4 . Triglycerides &gt; 400 mg/dL 5 . LDLcholesterol level &gt; 190 mg/dl 6 . History chronic renal insufficiency ( serum creatinine &gt; 2.0 mg/dl ) . 7 . History liver disease abnormal LFTs ( &gt; 2x upper limit normal ) 8 . Hemoglobin &lt; 10 mg/dL 9 . History congestive heart failure ( NYHA Class III IV ) 10 . Women pregnant lactate 11 . History nonskin malignancy within previous 5 year 12 . Any major active rheumatologic , pulmonary , dermatologic disease chronic inflammatory condition 13 . Surgery last 90 day 14 . History HIV positive 15 . Active alcohol drug abuse 16 . Active peptic ulcer disease 17 . Gout attack within past 6 month 18 . Participation investigational drug study within 6 week 19 . Serious unstable medical psychological condition , opinion investigator , would compromise subject ’ safety successful study participation 20 . Subjects warfarin may enrol , exclude optional adipose biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>HDL cholesterol</keyword>
	<keyword>Metabolic syndrome</keyword>
</DOC>